Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SH-114
- Development stage
- Unknown
- Lead developer
- Shorla Oncology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SH-114 is a ready-to-use (RTU) intravenous formulation of azacitidine, a pyrimidine nucleoside analog, developed by Shorla Oncology for the treatment of Myelodysplastic Syndromes (MDS). As an epigenetic modulator, azacitidine functions as a DNA methyltransferase inhibitor; upon incorporation into DNA, it covalently binds to and inhibits DNA methyltransferases, leading to DNA hypomethylation and the induction of cell differentiation or apoptosis in hematopoietic cells. The SH-114 formulation is designed to provide a stable, liquid presentation of the drug, eliminating the need for the complex reconstitution process required by the standard lyophilized powder formulation (Vidaza). This advancement is intended to improve clinical workflow efficiency and enhance provider safety by reducing the risk of accidental exposure to hazardous cytotoxic materials during preparation. SH-114 is currently in Phase 3 development.
- Other names
- azacitidine RTUready-to-use azacitidine
02
Targets
DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on SH-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH-114.